”Australia is an attractive place to conduct MedTech clinical research. This was the key topic at this morning’s MTPConnect session at the international MedTech conference. Key points:

Australia has a sophisticated medical research environment; there’s a streamlined clinical trials notification scheme with rapid approvals and a robust regulatory framework; the data collected is transferable and recognised by other regulatory authorities.

Australia is 28% cheaper than the US and 60% cheaper after tax incentives, for early phase clinical trials.

Australia has an ethnically diverse multi-lingual population; Western disease patterns; is close to Asian markets backed by Free Trade Agreements and has globally recognised KOLs in major therapeutic areas.

Australia has world-class clinical trials infrastructure with high quality facilities including for early phase device and preclinical studies; and established expertise in conducting device based trials.

Thank you to the speakers:
Peter McGauran
Daniel Grant
Jason Kovacic
Gemma Figtree
Falko Thiele

Presented by MTPConnect, Austrade and the Australian Cardiovascular Alliance.

HPG (Healthcare Professionals Group)